{"id":10159,"date":"2012-04-22T07:08:02","date_gmt":"2012-04-22T07:08:02","guid":{"rendered":"http:\/\/cardiophile.org\/?p=6901"},"modified":"2012-04-22T07:08:02","modified_gmt":"2012-04-22T07:08:02","slug":"vorapaxar-thrombin-receptor-antagonist-2","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/","title":{"rendered":"Vorapaxar \u2013 thrombin receptor antagonist"},"content":{"rendered":"

Vorapaxar \u2013 thrombin receptor antagonist<\/span><\/h2>\n

Vorapaxar \u2013 thrombin receptor antagonist: Vorapaxar is an oral protease-activated\u2013receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. Pierluigi Tricoci, Zhen Huang, Claes Held, David J Moliterno, Paul W Armstrong, Frans Van de Werf, Harvey D White, Philip E Aylward, Lars Wallentin, Edmond Chen, Yuliya Lokhnygina, Jinglan Pei, Sergio Leonardi, Tyrus L Rorick, Ann M Kilian, Lisa H K Jennings, Giuseppe Ambrosio, Christoph Bode, Angel Cequier, Jan H Cornel, Rafael Diaz, Aycan Erkan, Kurt Huber, Michael P Hudson, Lixin Jiang, J Wouter Jukema, Basil S Lewis, A Michael Lincoff, Gilles Montalescot, Jos\u00e9 Carlos Nicolau, Hisao Ogawa, Matthias Pfisterer, Juan Carlos Prieto, Witold Ruzyllo, Peter R Sinnaeve, Robert F Storey, Marco Valgimigli, David J Whellan, Petr Widimsky, John Strony, Robert A Harrington and Kenneth W Mahaffey, the TRACER Investigators [1] evaluated the role of vorapaxar in acute coronary syndrome, in a double-blind, randomized placebo controlled trial involving about thirteen thousand patients. They concluded that adding vorapaxar to standard therapy did not significantly reduce the primary composite endpoint, but increased the risk of major bleeding including intracranial hemorrhage.<\/p>\n

Reference<\/span><\/strong><\/p>\n

    \n
  1. Pierluigi Tricoci, Zhen Huang, Claes Held, David J Moliterno, Paul W Armstrong, Frans Van de Werf, Harvey D White, Philip E Aylward, Lars Wallentin, Edmond Chen, Yuliya Lokhnygina, Jinglan Pei, Sergio Leonardi, Tyrus L Rorick, Ann M Kilian, Lisa H K Jennings, Giuseppe Ambrosio, Christoph Bode, Angel Cequier, Jan H Cornel, Rafael Diaz, Aycan Erkan, Kurt Huber, Michael P Hudson, Lixin Jiang, J Wouter Jukema, Basil S Lewis, A Michael Lincoff, Gilles Montalescot, Jos\u00e9 Carlos Nicolau, Hisao Ogawa, Matthias Pfisterer, Juan Carlos Prieto, Witold Ruzyllo, Peter R Sinnaeve, Robert F Storey, Marco Valgimigli, David J Whellan, Petr Widimsky, John Strony, Robert A Harrington, Kenneth W Mahaffey, TRACER Investigators. Thrombin-receptor Antagonist Vorapaxar in Acute Coronary Syndromes<\/a>. N Engl J Med. 2012 Jan 5;366(1):20-33.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Vorapaxar to standard therapy did not reduce the primary composite end point, but increased risk of major bleeding including intracranial hemorrhage.<\/p>\n","protected":false},"author":1,"featured_media":36131,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-10159","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"\nVorapaxar \u2013 thrombin receptor antagonist<\/title>\n<meta name=\"description\" content=\"Vorapaxar \u2013 thrombin receptor antagonist: Did not reduce primary composite endpoint, but increased risk of major bleeding including intracranial hemorrhage.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vorapaxar \u2013 thrombin receptor antagonist\" \/>\n<meta property=\"og:description\" content=\"Vorapaxar \u2013 thrombin receptor antagonist: Did not reduce primary composite endpoint, but increased risk of major bleeding including intracranial hemorrhage.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2012-04-22T07:08:02+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/vorapaxar-thrombin-receptor-antagonist-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/vorapaxar-thrombin-receptor-antagonist-2\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Vorapaxar \u2013 thrombin receptor antagonist\",\"datePublished\":\"2012-04-22T07:08:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/vorapaxar-thrombin-receptor-antagonist-2\\\/\"},\"wordCount\":304,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/vorapaxar-thrombin-receptor-antagonist-2\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/vorapaxar-thrombin-receptor-antagonist-2\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/vorapaxar-thrombin-receptor-antagonist-2\\\/\",\"name\":\"Vorapaxar \u2013 thrombin receptor antagonist\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/vorapaxar-thrombin-receptor-antagonist-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/vorapaxar-thrombin-receptor-antagonist-2\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2012-04-22T07:08:02+00:00\",\"description\":\"Vorapaxar \u2013 thrombin receptor antagonist: Did not reduce primary composite endpoint, but increased risk of major bleeding including intracranial hemorrhage.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/vorapaxar-thrombin-receptor-antagonist-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/vorapaxar-thrombin-receptor-antagonist-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/vorapaxar-thrombin-receptor-antagonist-2\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/vorapaxar-thrombin-receptor-antagonist-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vorapaxar \u2013 thrombin receptor antagonist\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vorapaxar \u2013 thrombin receptor antagonist","description":"Vorapaxar \u2013 thrombin receptor antagonist: Did not reduce primary composite endpoint, but increased risk of major bleeding including intracranial hemorrhage.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/","og_locale":"en_US","og_type":"article","og_title":"Vorapaxar \u2013 thrombin receptor antagonist","og_description":"Vorapaxar \u2013 thrombin receptor antagonist: Did not reduce primary composite endpoint, but increased risk of major bleeding including intracranial hemorrhage.","og_url":"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2012-04-22T07:08:02+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Vorapaxar \u2013 thrombin receptor antagonist","datePublished":"2012-04-22T07:08:02+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/"},"wordCount":304,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/#primaryimage"},"thumbnailUrl":"","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/","url":"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/","name":"Vorapaxar \u2013 thrombin receptor antagonist","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/#primaryimage"},"thumbnailUrl":"","datePublished":"2012-04-22T07:08:02+00:00","description":"Vorapaxar \u2013 thrombin receptor antagonist: Did not reduce primary composite endpoint, but increased risk of major bleeding including intracranial hemorrhage.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/vorapaxar-thrombin-receptor-antagonist-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Vorapaxar \u2013 thrombin receptor antagonist"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/10159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=10159"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/10159\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=10159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=10159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=10159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}